Debt-to-equity of Viridian Therapeutics, Inc.\DE from 30 Sep 2017 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Viridian Therapeutics, Inc.\DE quarterly Debt-to-equity in % history and change rate from 30 Sep 2017 to 31 Dec 2025.
  • Viridian Therapeutics, Inc.\DE Debt-to-equity for the quarter ending 31 Dec 2025 was 16%, a 66% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Viridian Therapeutics, Inc.\DE Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 16% +6.4% +66% 31 Dec 2025
Q3 2025 12% +2.1% +22% 30 Sep 2025
Q2 2025 10% -0.4% -3.8% 30 Jun 2025
Q1 2025 9.9% -1% -9.5% 31 Mar 2025
Q4 2024 9.6% -2.3% -19% 31 Dec 2024
Q3 2024 9.6% -2.1% -18% 30 Sep 2024
Q2 2024 11% +1% +10% 30 Jun 2024
Q1 2024 11% +0.44% +4.2% 31 Mar 2024
Q4 2023 12% +1.4% +14% 31 Dec 2023
Q3 2023 12% +1.5% +15% 30 Sep 2023
Q2 2023 9.8% -1.2% -11% 30 Jun 2023
Q1 2023 10% +0.06% +0.57% 31 Mar 2023
Q4 2022 10% -1.1% -9.4% 31 Dec 2022
Q3 2022 10% -1.9% -16% 30 Sep 2022
Q2 2022 11% -6.1% -36% 30 Jun 2022
Q1 2022 10% -9% -47% 31 Mar 2022
Q4 2021 12% -14% -54% 31 Dec 2021
Q3 2021 12% -48% -80% 30 Sep 2021
Q2 2021 17% -46% -73% 30 Jun 2021
Q1 2021 19% -38% -66% 31 Mar 2021
Q4 2020 25% -27% -52% 31 Dec 2020
Q3 2020 60% +19% +49% 30 Sep 2020
Q2 2020 63% +30% +95% 30 Jun 2020
Q1 2020 58% +31% +117% 31 Mar 2020
Q4 2019 52% +29% +124% 31 Dec 2019
Q3 2019 40% +16% +65% 30 Sep 2019
Q2 2019 32% +9% +39% 30 Jun 2019
Q1 2019 27% +3.2% +13% 31 Mar 2019
Q4 2018 23% -0.88% -3.6% 31 Dec 2018
Q3 2018 24% -30% -55% 30 Sep 2018
Q2 2018 23% 30 Jun 2018
Q1 2018 24% 31 Mar 2018
Q4 2017 24% 31 Dec 2017
Q3 2017 55% 30 Sep 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.